Estimating effects of time-varying treatments: pitfalls and opportunities

Episodios

Penalization Theory and Practice for Cox Models
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Biomarker-based phase III clinical trial: Real-world experiences
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
¿Faltan episodios?

Pulsa aquí para actualizar resultados
Estimating effects of time-varying treatments: pitfalls and opportunities
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Evaluating and addressing consistency of the evidence in a network metaanalysis
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk Calculator
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
From model building to validation and back: a plea for robustness
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Using network meta-analysis for decision making
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapy
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Adaptive designs for confirmatory clinical trials with treatment selection
18 abr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculator
29 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
contribution and discussion
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Gene signatures as treatment modifiers in clinical trial
29 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Biomarker-based phase II trial designs
29 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy
29 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Causal search in high-dimensional settings
29 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Assessing mediation through multiple pathways using natural effect models
28 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
The meta-analytic approach to validation of surrogate endpoints
28 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
TBD (on meta-regression)
28 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Two folklores: ridge regression versus the lasso
27 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde
Purposeful penalization of likelihood in small samples
27 ago 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Ver Ver de nuevo Continuar Viendo...
- Ver más tarde Ver más tarde

Episodios

Penalization Theory and Practice for Cox Models

Biomarker-based phase III clinical trial: Real-world experiences

Evaluating and addressing consistency of the evidence in a network metaanalysis

Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk Calculator

From model building to validation and back: a plea for robustness

Using network meta-analysis for decision making

Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapy

Adaptive designs for confirmatory clinical trials with treatment selection

Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculator

Gene signatures as treatment modifiers in clinical trial

Biomarker-based phase II trial designs

Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy

Causal search in high-dimensional settings

Assessing mediation through multiple pathways using natural effect models

The meta-analytic approach to validation of surrogate endpoints

TBD (on meta-regression)

Two folklores: ridge regression versus the lasso

Purposeful penalization of likelihood in small samples